Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Normeperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.97 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Normeperidine SCHEMBL341796 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Normeperidine SCHEMBL8177568 | 0.97 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Normeperidine SCHEMBL4537496 | 0.97 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Normeperidine SCHEMBL27449404 | 0.91 | OPRM1 (0.85) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL17187978 | 0.90 | OPRM1 (0.84) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL23225662 | 0.88 | OPRM1 (0.79) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL6866343 | 0.87 | OPRM1 (0.79) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL8187471 | 0.87 | OPRM1 (0.78) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL11094110 | 0.85 | OPRM1 (0.75) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL23225663 | 0.84 | OPRM1 (0.75) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | OPRM1 69/4885OPRD1 111/4885OPRK1 7/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | OPRM1 69/4885OPRD1 111/4885OPRK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.